Predictive Diagnostics, Predictive Diagnostic Services | Reliance Life Sciences - LifeSciences
Businesses - Molecular Medicine - Predictive Diagnostics
Reliance Life Sciences is involved in Predictive Diagnostic testing in the field of Oncology, with the objective of predicting increased risk of developing a disease in the future based on a test done on an asymptomatic person (person who appears normal). Positive result only provides information about a person's risk of developing cancer. Reliance Life Sciences was the first organization to introduce BRCA 1/ BRCA 2 mutations testing for familial breast cancer in India. Reliance Life Sciences uses state-of-the-art technology of DNA sequencing - 'a gold standard', to detect mutations. Reliance Life Sciences offers both pre- and post-test genetic counseling and reports both, the alterations depicting the polymorphisms and mutations observed. Reliance Life Sciences has launched India’s first portal for Breast cancer genomics to help the medical fraternity to predict familial and/ or early onset breast cancer in Indian women.
Reliance Life Sciences also offers Preimplantation Genetic Screening (PGS) by advanced technology as next generation sequencing and Preimplantation Genetic Diagnosis (PGD) for Chromosomal aberrations (chromosomes 13, 18, 21, X & Y), Beta Thalassemia, Sickle cell anemia. It is a highly advanced, complex and technically demanding procedure and is an attractive means of preventing heritable genetic disease, thereby eliminating the dilemma of pregnancy termination following unfavorable prenatal diagnosis.
Reliance Life Sciences also provides predictive tests for RET gene mutations for familial Medullary Thyroid Cancer and Human Papilloma Virus (HPV) detection and typing by nucleotide sequencing, for predicting increased risk of cervical cancer.
Tests are also available for predicting the probability of an individual for stroke, heart attack etc. These tests study gene mutations in three Cardio-Vascular diseases (CVD) risk markers i.e. Factor V Leiden, MTHFR and Prothrombin, which accounts to around 45% of all the thrombotic risk factors.
Predictive Diagnostic Services
- BRCA 1 and 2 Mutations study for familial Breast and Ovarian Cancer by NGS
- NGS based PGS
- RET gene Mutation study for familial Medullary Thyroid Carcinoma
- BCR/ABL Mutation Analysis
- Cardio-Vascular Diseases (CVD) Risk Markers-
- Factor V Leiden
- MTHFR Mutation
- Prothrombin Mutation
- Maternally Inherited Cardiomyopathy (MICM)
- Maternal Myopathy with Cardiomyopathy (MMC)
- Human Papilloma Virus (HPV)
- HCV Genotyping
- HBV Drug Resistance Test
- HIV Drug Resistance Test
- Beta-Thalassemia Mutation Analysis
- PND for beta-Thalassemia
- PGD for Beta-Thalassemia
- PGD for Sickle cell anemia
- QF PCR
- Y-Chromosome Microdeletions
- Cystic Fibrosis